Increasing evidence indicates that PLK4 is aberrantly expressed in patient‐derived tumor samples, including colorectal cancer,13, 14 breast cancer,15, 16 bladder cancer,17 and melanoma,18 but is also expressed at low levels in proliferative tissues.19, 20, 21. Here, PLK4 is linked to neoplasm.